SynthesisEuropean urology2022
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
Synthesis in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07198451 (Efficacy Evaluation of Submucosal Injection of Gemcitabine in Preventing Recurrence of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer), which is not on this map. Cited by 70 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy Evaluation of Submucosal Injection of Gemcitabine in Preventing Recurrence of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized, Single-Blind, Multicenter Clinical Study
Who cites it
70 citing papers in PubMed, 4 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors: An Umbrella Meta-Analysis.JAMA network open · 2026Pooled it
- Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.Urologic oncology · 2025Pooled it
- SEOM-SOGUG clinical guideline for urothelial cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Guideline
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.The New England journal of medicine · 2025Trial
- Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.Japanese journal of clinical oncology · 2023Trial
- Multitask Deep Learning Model for Predicting Lymph Node Metastasis and Disease-Free Survival From Cytology Images in Bladder Cancer: A Multicenter Study With Pan-Cytology Validation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The cGAS-STING pathway contributes to cisplatin-induced skeletal muscle atrophy through altered proteostasis and myogenic signaling.Cell communication and signaling : CCS · 2026Article
- Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.Materials today. Bio · 2026Article
- Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.Medicina (Kaunas, Lithuania) · 2026Article
- MDM4 promotes chemoresistance in bladder cancer by attenuating P53-mediated EMT.Translational andrology and urology · 2026Article
- Scientific advances in drug development and clinical trials for urothelial carcinoma: Highlights from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.Asian journal of urology · 2026Article
- The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.The Journal of clinical investigation · 2026Review
- Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany.Oncology and therapy · 2026Article
- Article
- Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis.BMC complementary medicine and therapies · 2026Article
- Baicalin chemosensitivity enhancement of cisplatin in bladder cancer via autophagy flux inhibition.Frontiers in pharmacology · 2026Article
- Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy.Theranostics · 2026Article
- The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.Cancers · 2025Review
- State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes.Human vaccines & immunotherapeutics · 2025Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 14 institutions in 7 countries.
Funding
Abstract
contextOur prior systematic review and meta-analysis of individual participant data (IPD) suggesting a benefit of adjuvant chemotherapy for muscle-invasive bladder cancer was limited by the number and size of included randomised trials. We have updated results to include additional trials, providing the most up-to-date and reliable evidence of the effects of this treatment.
objectiveTo investigate the role of adjuvant cisplatin-based chemotherapy in the treatment of muscle-invasive bladder cancer. EVIDENCE ACQUISITION: Published and unpublished trials were sought via searches of bibliographic databases, trials registers, conference proceedings, and hand searching. Updated IPD were centrally collected, checked, and analysed. Results from individual randomised controlled trials (RCTs) were combined using a two-stage fixed-effect model. Prespecified analyses explored any variation in effect by trial and participant characteristics. EVIDENCE SYNTHESIS: Analyses of ten RCTs (1183 participants) demonstrated a benefit of cisplatin-based adjuvant chemotherapy on overall survival (hazard ratio [HR] = 0.82, 95% confidence interval [CI] = 0.70-0.96, p = 0.02). This represents an absolute improvement in survival of 6% at 5 yr, from 50% to 56%, and a 9% absolute benefit when adjusted for age, sex, pT stage, and pN category (HR = 0.77, 95% CI = 0.65-0.92, p = 0.004). There was no clear evidence that the effect varied by trial or participant characteristics. Adjuvant chemotherapy was also shown to improve recurrence-free survival (HR = 0.71, 95% CI = 0.60-0.83, p < 0.001), locoregional recurrence-free survival (HR = 0.68, 95% CI = 0.55-0.85, p < 0.001), and metastasis-free survival (HR = 0.79, 95% CI = 0.65-0.95, p = 0.01), with absolute benefits of 11%, 11%, and 8%, respectively.
conclusionsThis systematic review and meta-analysis demonstrates that cisplatin-based adjuvant chemotherapy is a valid option for improving outcomes for muscle-invasive bladder cancer. PATIENT SUMMARY: We looked at the effect of cisplatin-based chemotherapy on outcomes in participants with muscle-invasive bladder cancer. We gathered this information from eligible randomised controlled trials. We demonstrated that cisplatin-based chemotherapy is a valid option for improving outcomes of muscle-invasive bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.